

Jim Doyle Governor

Helene Nelson Secretary Department of Health and Family Services

1 WEST WILSON STREET PO BOX 309 MADISON WI 53701-0309

Telephone: 608-266-8922 FAX: 608-266-1096 TTY: 608-261-7798 dhfs.wisconsin.gov

# OPEN MEETING NOTICE

## MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE

Wednesday, March 29, 2006 1:30 p.m. – 5:00 p.m. The Madison Concourse Hotel – Wisconsin Ballroom 1 W. Dayton Street Madison, Wisconsin 53703

#### **AGENDA**

1:30 p.m. – 1:45 p.m.

Opening

Remarks/Introductions

II. Approval of Minutes

**III.** Conflict of Interest

IV. Decisions of the Secretary

1:45 p.m. – 4:00 p.m.

V. Public Comment

4:00 p.m. - 4:10 p.m. **VI. Break** 

4:10 p.m. – 4:35 p.m. **VII. Discussion of** 

I.

Manufacturer-Specific Supplemental Rebate Amounts (Closed Session)\*

4:35 p.m. – 5:00 p.m. VIII. Therapeutic Class Review,

Committee Discussion and Response to Proposal (Open Session)

Contact Person: Rita Hallett (608) 267-0938, E-mail - <a href="mailto:haller@dhfs.state.wi.us">haller@dhfs.state.wi.us</a>

**Accessibility:** The meeting is accessible for people with mobility impairments. Handicapped parking is available in the parking lot of the hotel. Accessible entrances are found in the parking ramp or in front of the building. People needing special accommodations to attend or participate in the meeting should notify the contact person at least five working days prior to the meeting.

Posted - State Capitol Building

Posted - 1 W. Wilson St., Madison

cc: State Editor, Milwaukee Journal Sentinel State Editor, The Capital Times

State Editor, Wisconsin State Journal

#### **Drug Class for Review:**

 Atypical Antipsychotics (Schizophrenia and Bipolar Disorders)

Note: the first portion of public comment is reserved for consumers. Please see public testimony guidelines for registration instructions. Walk-in registrations may be limited by time availability

<sup>\*</sup> Intended for consideration in closed session pursuant to s. 19.85(1)(e), Wis. Stats.

### **Medicaid Prior Authorization Advisory Committee Meeting**

## **Public Testimony Guidelines:**

- 1. Speakers are required to sign up with the Division of Health Care Financing (DHCF) prior to the meeting. Please contact Rita Hallett via e-mail at <a href="mailto:haller@dhfs.state.wi.us">haller@dhfs.state.wi.us</a> or by phone at (608) 267-0938 to reserve a time slot.
- 2. Speakers must complete the Wisconsin Medicaid Pharmacy Prior Authorization Committee Presenter/Witness Disclosure form prior to providing testimony. This form will be e-mailed to you with your approximate speaking time.
- 3. Speakers must sign in when arriving at the meeting and return completed Presenter/Witness Disclosure forms to DHCF staff prior to speaking. Forms will also be available at the registration table.
- 4. Speakers must submit a written copy of their testimony to Rita Hallett, either prior to or at the meeting. Testimony copies may be submitted via e-mail at <a href="mailto:hallet@dhfs.state.wi.us">hallet@dhfs.state.wi.us</a> or mailed to the Division of Health Care Financing, Attn: Rita Hallett, 1 W. Wilson Street, Room 350, Madison, WI 53702.
- 5. Should all slots for spoken testimony become filled, parties are invited to submit written testimony for review and consideration by the committee. Written testimony should be submitted to Rita Hallett via e-mail at <a href="mailto:haller@dhfs.state.wi.us">haller@dhfs.state.wi.us</a> or mailed to the Division of Health Care Financing, Attn: Rita Hallett, 1 W. Wilson Street, Room 350, Madison, WI 53702.
- 6. Only one speaker per company or organization will be permitted.
- 7. Speakers will be required to state name, address, organization represented, and the drug name and class applicable to their testimony.
- 8. Speakers will be limited to a period of 5 minutes.
- 9. Speakers will NOT be permitted to use audio/visual equipment during their presentation.
- 10. Speakers will NOT be permitted to provide handouts to the Prior Authorization Committee members prior to or during the meeting.
- 11. Prior Authorization Committee members will not ask questions or respond to speakers during the public testimony.
- 12. Speakers are welcome to remain for Committee deliberations. Committee members may elect to address questions to speakers who gave testimony earlier.